{
    "clinical_study": {
        "@rank": "16767", 
        "acronym": "Lina-Plaque", 
        "arm_group": [
            {
                "arm_group_label": "Linagliptin", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will receive 5 mg linagliptin once daily for a period of 6 months."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will take placebo tablets once daily for a period of 6 months."
            }
        ], 
        "brief_summary": {
            "textblock": "Examination of the effect of Linagliptin versus placebo for 6 months on vascular\n      inflammation of the carotic artery and on abdominal adipose tissue inflammation in patients\n      with diabetes mellitus type 2. The effect will be assessed by FDG-PET scan.\n\n      Furthermore the effect of Linagliptin on the vessel wall volume of the carotid artery will\n      be assessed by MRI scan and biomarkers of vascular inflammation will be analyzed in blood\n      samples."
        }, 
        "brief_title": "Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes Mellitus Type 2 (T2DM),", 
            "Vascular Inflammation,", 
            "Plaque Morphology"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Inflammation"
            ]
        }, 
        "detailed_description": {
            "textblock": "As part of the screening a PET-CT scan is executed to examine baseline vascular inflammation\n      of the carotid artery and to evaluate abdominal adipose tissues inflammation.\n\n      Patients who are eligible to participate in the study according to the in- and exclusion\n      criteria will be randomised in one of the two study arms.\n\n      According to the randomisation the patients will receive 5 mg Linagliptin or placebo per day\n      for a period of 6 months.\n\n      To evaluate the effect of Linagliptin versus placebo the vessel wall volume of the artery\n      will be assessed by MRI scan and the vascular inflammation of the carotid artery by FDG-PET,\n      furthermore the vascular inflammation will be analyzed by biomarkers in blood samples and\n      the abdominal adipose tissue inflammation will investigated by subcutaneous adipose tissue\n      biopsies."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Diabetes mellitus Type 2\n\n          2. HbA1c > 7%\n\n          3. Age > 50 years\n\n          4. Coronary artery disease or carotid artery disease\n\n          5. 18F-FDG uptake of the carotid arterial wall to background (blood) ratio > 1.8\n\n          6. Written informed consent prior to study participation\n\n          7. Stable anti-diabetic and cholesterol lowering medication for the last 3 month\n\n          8. Stable anti-diabetic medication for the last 6 weeks which should include a maximal\n             tolerated dose of metformin (unless contraindication or intolerance to metformin does\n             exist);\n\n          9. Indication to increase anti-diabetic medication as judged by the investigator\n\n        Exclusion Criteria:\n\n          1. Diabetes mellitus type 1\n\n          2. Use of DPP-4 Inhibitor, GLP-1 agonists, Thiazolindinedione\n\n          3. Kidney disease CKD 4 and more (GFR < 30 ml/min/1.73)\n\n          4. Liver disease (ALT or AST > 3 times the upper limit of norm) or known liver cirrhosis\n\n          5. Any reason for not being able to sustain the imaging studies\n\n          6. Pacemaker/ICD/metallic clips in close relation to vessels in the brain\n\n          7. Uncontrolled thyroid disease\n\n          8. Active malignant disease\n\n          9. Chronic inflammatory disease\n\n         10. Chronic use of NSAR or cortison\n\n         11. HbA1c > 8.5%\n\n         12. Recent (<3 months) clinically significant coronary or cerebral vascular event\n\n         13. Pregnant females as determined by positive [serum or urine] HCG test at Screening or\n             prior to dosing\n\n         14. Lactating females\n\n         15. The subject has a history of any other illness, which, in the opinion of the\n             Investigator, might pose an unacceptable risk by administering study medication\n\n         16. The subject received an investigational drug within 30 days prior to inclusion into\n             this study\n\n         17. The subject has any current or past medical condition and/or required medication to\n             treat a condition that could affect the evaluation of the study\n\n         18. The subject is unwilling or unable to follow the procedures outlined in the protocol\n\n         19. The subject is mentally or legally incapacitated"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02077309", 
            "org_study_id": "12-027", 
            "secondary_id": [
                "111/13", 
                "2012-003859-12"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Linagliptin", 
                "intervention_name": "Linagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Trade name Trajenta\u00ae by Boehringer Ingelheim (BI) Pharma GmbH & Co KG, Biberach, Germany"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Produced by Boehringer Ingelheim (BI) Pharma GmbH & Co KG, Biberach, Germany"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "BI 1356"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "T2DM,", 
            "vascular inflammation,", 
            "18-FDG-PET,", 
            "plaque morphology,", 
            "MRI,", 
            "DPP-4 Inhibition"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "contact": {
                "email": "nmarx@ukaachen.de", 
                "last_name": "Nikolaus Marx, Univ.-Prof.", 
                "phone": "+49 241 80 89301"
            }, 
            "contact_backup": {
                "email": "asudhoff@ukaachen.de", 
                "last_name": "Angela Sudhoff, M.Sc.", 
                "phone": "+49 241 80 37429"
            }, 
            "facility": {
                "address": {
                    "city": "Aachen", 
                    "country": "Germany", 
                    "zip": "52074"
                }, 
                "name": "Department of Internal Medicine I, University Hospital"
            }, 
            "investigator": {
                "last_name": "Michael Lehrke, PD Dr. med.", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Linagliptin as a Modulator of Vascular Inflammation in Patients With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "email": "nmarx@ukaachen.de", 
            "last_name": "Nikolaus Marx, Univ.-Prof.", 
            "phone": "+49 241 80 89301"
        }, 
        "overall_contact_backup": {
            "email": "mlehrke@ukaachen.de", 
            "last_name": "Michael Lehrke, PD Dr. med.", 
            "phone": "+49 241 8089301"
        }, 
        "overall_official": {
            "affiliation": "Department of Internal Medicine I, RWTH Aachen University Hospital", 
            "last_name": "Nikolaus Marx, Univ.-Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Examination of the effect of 5 mg linagliptin qd versus placebo on vascular inflammation of the carotic artery by FDG-PET in patients with diabetes mellitus within 6 months.", 
            "measure": "Effect of linagliptin on vascular inflammation of the carotic artery", 
            "safety_issue": "No", 
            "time_frame": "up to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02077309"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Examination of the effect of 5mg linagliptin qd versus placebo on vessel wall volume of the carotid artery by MRI scan.", 
                "measure": "Effect of linagliptin on vessel wall volume of the carotid artery", 
                "safety_issue": "No", 
                "time_frame": "baseline and 6 months"
            }, 
            {
                "description": "Evaluation of the effect of 5mg linagliptin qd versus placebo on abdominal adipose tissue inflammation by FDG-PET in addition to adipose tissue biopsies.", 
                "measure": "Effect of linagliptin on abdominal adipose tissue inflammation", 
                "safety_issue": "No", 
                "time_frame": "baseline and 6 months"
            }, 
            {
                "description": "Blood analysis to examine the effect of linagliptin on biomarkers of vascular inflammation.", 
                "measure": "Effect of linagliptin on biomarkers of vascular inflammation", 
                "safety_issue": "No", 
                "time_frame": "baseline and 6 months"
            }
        ], 
        "source": "RWTH Aachen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "RWTH Aachen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}